Clarity Pharmaceuticals

Clarity Pharmaceuticals es una de las ...

• S&P/ASX200.

Clarity Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización CU6 (AU).

Ver el organigrama con sus 18 ejecutivos principales

Biografías más buscadas en Clarity Pharmaceuticals

• Michelle Parker, Chief Executive Officer
• Chris Roberts, Non-Executive Director
• Colin Biggin, Excecutive Director

Recientes movimientos de ejecutivos en Clarity Pharmaceuticals

• Colin Biggin que ha sido Director, Managing Director and Chief Executive Officer, pasa a ser Excecutive Director  (noticia publicada el 14 de octubre de 2024).
• Michelle Parker que ha sido Director and Executive Vice President, Global Clinical Operations, ha ascendido a Chief Executive Officer  (noticia publicada el 14 de octubre de 2024).
• Robert Thomas, Lead Independent Director, está a punto de jubilarse  (noticia publicada el 26 de agosto de 2024).

Haga clic aquí para ver otros movimientos en Clarity Pharmaceuticals

Crear su alerta
para seguir los movimientos de los ejecutivos en Clarity Pharmaceuticals.

Clarity Pharmaceuticals tiene 1.833 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacia

• Jazz Pharmaceuticals ha Chimerix adquirido (publicado el 6 de marzo de 2025).
• Cosette Pharmaceuticals has announced the acquisition of Mayne Pharma  (publicado el 25 de febrero de 2025).
• Bain Capital ha Mitsubishi Tanabe Pharma adquirido (publicado el 12 de febrero de 2025).

Otros contactos sugeridos en el sector Farmacia

• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Paul Meister - Chairman of the Board en Amneal Pharmaceuticals
• Seth Harrison - Chairman and Director en Braeburn Pharmaceuticals

Saber más sobre el sector Farmacia >

Últimos comunicados de prensa de Clarity Pharmaceuticals

• Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity’s COBRA study selected as a Top-Rated Oral Presentation at prestigious industry Annual Meeting - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity promotes Michelle Parker to CEO - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Copper-67 SAR-bisPSMA updates - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity launches $121 million fully underwritten equity raising - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity successfully completes Placement and Institutional Entitlement Offer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• SECuRE update: First participant treated in the last cohort of dose escalation - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity’s theranostic prostate cancer trial advances to multi-dose phase - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• View more press releases Close

Redes sociales sobre Clarity Pharmaceuticals

• Clarity Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Clarity Pharmaceuticals en LinkedIn, Twitter y YouTube